Abstract: Use in the prevention and/or in the treatment of neurodegenerative diseases of 2-amino-4-phenyl-4-oxo-butyric acid derivatives which act as kynureninase enzyme inhibitors and/or kynurenine-3-hydroxylase enzyme inhibitors.

Abstract: An N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compound of the formula (I): wherein X, Y, W and R are as defined herein.

Abstract: A fluoro-substituted benzoylpropionic acid compound of formula (I) either as a single optical isomer or as a mixture of optical isomers ##STR1## wherein R is hydroxy, amino, hydroxylamine, --OR', --NHR', N(R').sub.2 or --NHOR' in which R' is C.sub.1 -C.sub.6 alkyl or benzyl;or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT).The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, andR.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino,with the provisos that:(i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and(ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.

Abstract: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT).

Abstract: The present invention concerns the use of 4-amino-1-(2-pyridyl)piperidines of general formula (I') ##STR1## wherein R' represents hydrogen, a halogen atom, a methyl, methylthio, trifluoromethyl, trifluoromethylthio, (C.sub.1 -C.sub.3)alkoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, or phenoxy group optionally substituted with a halogen atom, a trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, (C.sub.1 -C.sub.3)alkylthio, or cyano group, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of those conditions deriving from disorders of the serotoninergic systems wherein a serotoninergic action selectively mediated by the 5-HT.sub.3 receptors is required, e.g. affective disorders, anxiety, psychotic troubles, constipation.

Abstract: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT).The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, andR.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino; with the provisos that(i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and(ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.

Abstract: The invention concerns a method of treatment and prophylaxis of depression and stress by means of a phenylethanolaminotetralin of formula (I) ##STR1## wherein A is a (C.sub.1 -C.sub.4)alkylene radical and R represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, or a pharmaceutically acceptable salts thereof.

Abstract: A method of prophylaxis and/or treatment of intestinal motility disorders, in particular of constipation, in mammals which comprises administering to a mammal in need of such a treatment a prophylactically and/or therapeutically effective amount of a compound of formula (I) ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene radical, andR represents a cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, p-tolyl, pyridyl, pyridyl 1-oxide, or naphthyl group, or of a pharmaceutically acceptable salt thereof.

Abstract: Aryloxypropanolaminotetralins with beta-antagonist activity of the formula ##STR1## wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group, in optically active or inactive form as well as their acid addition salts are described.A process for their preparation and pharmaceutical compositions containing the compounds of formula (i) or their pharmaceutically acceptable acid addition salts, are also described.

Abstract: A method of prophylaxis and/or treatment of intestinal motility disorders, in particular of constipation, in mammals which comprises administering to a mammal in need of such a treatment a prophylactically and/or therapeutically effective amount of a compound of formula (I) ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene radical, andR represents a cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, p-tolyl, pyridyl, pyridyl 1-oxide, or naphthyl group, or of a pharmaceutically acceptable salt thereof.

Abstract: A method of treatment of anxiety and depression in mammals is described which comprises administering to a mammal in need thereof an effective amount of a trifluoromethylphenyl-tetrahydropyridine derivative of formula I ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene chain and R is selected from the group consisting of cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, pyridyl, 1-oxide-pyridyl and naphthyl, or of a pharmaceutically acceptable salt thereof.

Abstract: Phenylethanolamine analog active compounds, optionally substituted on the phenyl group with an halogen atom or with an alkyl or trifluoromethyl group and substituted on the amino group with a phenylalkyl or phenoxy alkyl group optionally substituted on the benzene ring, are used for the treatment and/or prophylaxis of gastrointestinal diseases associated with a smooth muscle contraction.

Abstract: Methyllevallorphanium salts having peripheral antagonistic activity of formula ##STR1## wherein Y.sup.n(-) represents the anion a pharmaceutically acceptable acid other than halogen and n represents the number of negative charges of said anion; a process for their preparation by exchange of the halogen ion with the Y.sup.n(-) anion; and pharmaceutical compositions containing them as active ingredients.

Abstract: A novel phenylethanolaminotetraline having lipolytic activity of formula ##STR1## wherin X represents hydrogen, halogen, a trifluoromethyl or a lower alkyl group and R represents hydrogen, a lower alkyl group not substituted or substituted by a cycloalkyl group containing 3 to 7 carbon atoms, a hydroxy group, a lower alkoxy, carboxy or lower carbalkoxy group; a cycloalkyl group containing 3 to 7 carbon atoms; or a lower alcanoyl group; or a pharmaceutically acceptable salt thereof; a process for its preparation; and pharmaceutical compositions containing it as active ingredient, useful for the treatment of obesity.

Abstract: The invention relates to 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines of formula ##STR1## in which R represents a cyano, acetyl or cycloalkyl group of from 3 to 7 carbon atoms and Alk represents a straight or branched alkylene of from 1 to 4 carbon atoms, as well as to the salts thereof, having an anorectic acitivity, to a process for preparing same and to pharmaceutical compositions containing said compounds, useful in the treatment of obesity.

Abstract: The invention relates to 4-(-3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines of formula ##STR1## in which R represents a cyano, acetyl or cycloalkyl group of from 3 to 7 carbon atoms and Alk represents a straight or branched alkylene of from 1 to 4 carbon atoms, as well as to the salts thereof, having an anorectic activity, to a process for preparing same and to pharmaceutical compositions containing said compounds, useful in the treatment of obesity.

Abstract: The invention relates to 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridines of formula ##STR1## in which R represents a cyano, acetyl or cycloalkyl group of from 3 to 7 carbon atoms and Alk represents a straight or branched alkylene of from 1 to 4 carbon atoms, as well as to the salts thereof, having an anorectic activity, to a process for preparing same and to pharmaceutical compositions containing said compounds, useful in the treatment of obesity.

Abstract: Amidobenzamides acting as histamine H.sub.2 receptors blocking agents, of formula ##STR1## wherein A is CO or SO.sub.2 and B is alkyl, phenyl, pyridyl, pyridyl-1-oxyde, pyrazinyl or thienyl; their salts; process for their preparation by reaching 2-(5-dimethyl-aminomethylfuran-2-ylmethylthio)ethylamine with a derivative of formula ##STR2## and optional salification and pharmaceutical compositions containing same.

Abstract: The present invention provides 1-(p-azidobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid and its pharmaceutically acceptable salts and esters and processes of preparation.